Replies to post #199945 on Anavex Life Sciences Corp (AVXL)

[nidan7500]

As discussed many times here by Xena and others...maybe this will break the cycle. The lack of credibility here is a "SHOCK" to many who keep a childlike faith that the system must be right.

https://endpts.com/top-alzheimers-researcher-paul-aisen-apologizes-for-ethics-integrity-breach-as-usc-pays-50m-to-settle-poaching-lawsuit/

In addition to being a professor at UCSD, Aisen was named director of the Alzheimer’s Disease Cooperative Study back in 2007. The ADCS is a research consortium that plays a key role in undertaking large Alzheimer’s drug studies. Aisen has done considerable work advising Eli Lilly on its late-stage drug solanezumab, at one point reportedly playing a key role in persuading Lilly to take the drug back into Phase III — where it failed.

It's easy to fill in a few blanks. Japanese quality professionals have a well established practice known as "5 WHY's". Simply continue to ask the "why" question to get to a solution. It is effective. Had anyone even done that simple process here we all would have saved time, which is the most important element lost by patients.

Now my question is...WHY didn't the FDA do a similar exercise w/those people and processes in use? Are they still in use? WHY?

[bas2020]

Wow, does that ever smell. Sure changes my opinion of Aisen, his ethics and his ties to BP. So, is he an honest and forthright contributor of Anavex's SAB or rather a "spy"? Let's hope he's not so much in BP's pocket that he keeps us out of ACTC. Not that Anavex needs ACTC, but the inclusion would bode well.

[Gator328]

“Aisen’s work, though, has been a leader in high-priced failures. No drug has yet to survive the trial process for bending the disease’s progression, and after Biogen’s massive fail on aducanumab, some investigators are going back to the drawing board in a reassessment of the basic theories that Aisen helped birth.”

Yup, just the guy I want advising Anavex.

Missling should cut ties with this guy ASAP